We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00045006
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : May 30, 2013
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced cancer.

Condition or disease Intervention/treatment Phase
Cancer Drug: vorinostat Phase 1

Detailed Description:


  • Determine the maximum tolerated dose of suberoylanilide hydroxamic acid in patients with advanced solid tumors or hematologic malignancies.
  • Evaluate the pharmacokinetic profile of this drug in these patients.
  • Determine the effects of this drug on absorption in the fasting and non-fasting states in these patients.
  • Determine any anti-tumor effects of this drug in these patients.
  • Correlate clinical outcomes with histone acetylation in circulating mononuclear cells and tumor biopsy samples in patients treated with this drug.

OUTLINE: This is a dose-escalation study. Patients are stratified according to disease (solid tumor vs multiple myeloma or lymphoma vs leukemia or myelodysplastic syndromes).

The initial 15-20 patients (in the solid tumor or multiple myeloma or lymphoma stratum) receive suberoylanilide hydroxamic acid (SAHA) IV over 2 hours on day 1 of week 0 and then orally once or twice daily beginning on day 1 of week 1. All remaining patients receive oral SAHA once or twice daily beginning on day 1 of week 1. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

In each stratum, cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed monthly for resolution of adverse events.

PROJECTED ACCRUAL: A maximum of 114 patients (42 with solid tumors, 36 with lymphoma or multiple myeloma, and 36 with leukemia or myelodysplastic syndromes) will be accrued for this study within 1 year.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies
Study Start Date : July 2001
Actual Primary Completion Date : December 2005
Actual Study Completion Date : July 2008

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • One of the following diagnoses:

    • Histologically confirmed advanced primary or metastatic solid tumor, including, but not limited to, the following:

      • Androgen-independent prostate cancer
      • Breast cancer
      • Ovarian cancer
      • Head and neck cancer
      • Non-small cell lung cancer
      • Bladder cancer
      • Kidney cancer
    • Diagnosis of lymphoma, multiple myeloma, leukemia, or myelodysplastic syndromes (MDS), including, but not limited to, the following:

      • Intermediate-grade or follicular non-Hodgkin's lymphoma
      • Hodgkin's lymphoma
  • Patients with lymphoma or multiple myeloma must be ineligible for peripheral blood stem cell transplantation
  • For patients with solid tumors (except prostate cancer):

    • Disease progression based on development of new lesions or an increase in pre-existing lesions
    • Biochemical marker increase must not be sole criterion for disease progression
  • For prostate cancer patients only:

    • Disease progression based on rising prostate-specific antigen (PSA) values, transaxial imaging, or radionuclide scans
    • Increase in disease-related symptoms must not be sole manifestation of progression
    • Patients receiving an antiandrogen as part of first-line hormonal therapy must show disease progression off of the antiandrogen prior to study
    • Biochemical progression (at least 25% increase over range of values) defined as 1 of the following:

      • Rising PSA documented by at least 3 consecutive measurements obtained at least 1 week apart
      • Rising PSA documented by at least 2 consecutive measurements obtained more than 1 month apart
    • PSA at least 4 ng/mL

      • Testosterone no greater than 50 ng/mL
      • If no prior orchiectomy, must maintain castrate levels of testosterone
  • Disease must be refractory to standard therapy or for which no curative therapy exists
  • No active CNS or epidural tumors
  • Hormone receptor status:

    • Not specified NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.



  • 18 and over


  • Male or female

Menopausal status

  • Not specified

Performance status

  • Karnofsky 70-100%

Life expectancy

  • Not specified


  • WBC at least 3,500/mm^3
  • Platelet count at least 100,000/mm^3 (patients with solid tumors)
  • Platelet count greater than 25,000/mm^3 (patients with hematologic malignancy)
  • Absolute neutrophil count at least 500/mm^3 (patients with hematologic malignancy)


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST and ALT no greater than 3 times ULN
  • PT no greater than 15 seconds


  • Creatinine no greater than 2.0 mg/dL


  • No New York Heart Association class III or IV heart disease


  • No severe debilitating pulmonary disease


  • No infection requiring IV antibiotics
  • No other severe medical problems that would preclude study participation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy

  • See Disease Characteristics


  • At least 4 weeks since prior chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • At least 4 weeks since prior ketoconazole
  • At least 2 weeks since prior steroids for patients with lymphoma
  • Concurrent gonadotropin-releasing hormone analogs or diethylstilbestrol to maintain castrate levels of testosterone allowed for prostate cancer patients
  • No concurrent ketoconazole


  • At least 4 weeks since prior radiotherapy
  • No concurrent radiotherapy to sole measurable lesion


  • See Disease Characteristics
  • No concurrent surgery


  • Recovered from all prior therapy
  • At least 4 weeks since prior palliative therapy for solid tumor patients with progressive metastatic disease (if present)
  • At least 4 weeks since prior investigational anticancer therapeutic drugs
  • At least 2 weeks since prior conventional cytotoxic therapy for patients with leukemia or MDS
  • At least 4 weeks since prior investigational therapy for patients with leukemia or MDS
  • No other concurrent investigational drugs
  • No other concurrent anticancer agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00045006

Layout table for location information
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: William K. Kelly, DO Memorial Sloan Kettering Cancer Center
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00045006    
Other Study ID Numbers: MSKCC-01021
CDR0000256306 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: May 30, 2013
Last Verified: October 2003
Keywords provided by National Cancer Institute (NCI):
acute undifferentiated leukemia
de novo myelodysplastic syndromes
borderline ovarian surface epithelial-stromal tumor
ovarian sarcoma
ovarian stromal cancer
previously treated myelodysplastic syndromes
prolymphocytic leukemia
recurrent adult Hodgkin lymphoma
recurrent adult T-cell leukemia/lymphoma
recurrent adult acute lymphoblastic leukemia
recurrent adult acute myeloid leukemia
recurrent adult diffuse large cell lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent bladder cancer
recurrent breast cancer
recurrent cutaneous T-cell non-Hodgkin lymphoma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent metastatic squamous neck cancer with occult primary
recurrent mycosis fungoides/Sezary syndrome
recurrent non-small cell lung cancer
recurrent ovarian epithelial cancer
recurrent ovarian germ cell tumor
recurrent prostate cancer
recurrent renal cell cancer
refractory chronic lymphocytic leukemia
refractory hairy cell leukemia
refractory multiple myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action